|
1
|
Justo N, Wilking N, Jönsson B, Luciani S
and Cazap E: A review of breast cancer care and outcomes in Latin
America. Oncologist. 18:248–256. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Key TJ, Verkasalo PK and Banks E:
Epidemiology of breast cancer. Lancet Oncol. 2:133–140. 2001.
View Article : Google Scholar
|
|
3
|
Ambros V: microRNAs: Tiny regulators with
great potential. Cell. 107:823–826. 2001. View Article : Google Scholar
|
|
4
|
de Moor CH, Meijer H and Lissenden S:
Mechanisms of translational control by the 3′ UTR in development
and differentiation. Semin Cell Dev Biol. 16:49–58. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
He H, Jazdzewski K, Li W, Liyanarachchi S,
Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, et al:
The role of microRNA genes in papillary thyroid carcinoma. Proc
Natl Acad Sci USA. 102:19075–19080. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Scott GK, Goga A, Bhaumik D, Berger CE,
Sullivan CS and Benz CC: Coordinate suppression of ERBB2 and ERBB3
by enforced expression of micro-RNA miR-125a or miR-125b. J Biol
Chem. 282:1479–1486. 2007. View Article : Google Scholar
|
|
11
|
Wu ZS, Wu Q, Wang CQ, Wang XN, Huang J,
Zhao JJ, Mao SS, Zhang GH, Xu XC and Zhang N: miR-340 inhibition of
breast cancer cell migration and invasion through targeting of
oncoprotein c-Met. Cancer. 117:2842–2852. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang R, Wang ZX, Yang JS, Pan X, De W and
Chen LB: MicroRNA-451 functions as a tumor suppressor in human
non-small cell lung cancer by targeting ras-related protein 14
(RAB14). Oncogene. 30:2644–2658. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang J, Guo H, Zhang H, Wang H, Qian G,
Fan X, Hoffman AR, Hu JF and Ge S: Putative tumor suppressor
miR-145 inhibits colon cancer cell growth by targeting oncogene
Friend leukemia virus integration 1 gene. Cancer. 117:86–95. 2011.
View Article : Google Scholar
|
|
14
|
Ma L, Young J, Prabhala H, Pan E, Mestdagh
P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S,
et al: miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin
and cancer metastasis. Nat Cell Biol. 12:247–256. 2010.PubMed/NCBI
|
|
15
|
Ma L, Teruya-Feldstein J and Weinberg RA:
Tumour invasion and metastasis initiated by microRNA-10b in breast
cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Valastyan S, Reinhardt F, Benaich N,
Calogrias D, Szász AM, Wang ZC, Brock JE, Richardson AL and
Weinberg RA: A pleiotropically acting microRNA, miR-31, inhibits
breast cancer metastasis. Cell. 137:1032–1046. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tavazoie SF, Alarcón C, Oskarsson T, Padua
D, Wang Q, Bos PD, Gerald WL and Massagué J: Endogenous human
microRNAs that suppress breast cancer metastasis. Nature.
451:147–152. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chiang AC and Massagué J: Molecular basis
of metastasis. N Engl J Med. 359:2814–2823. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Talmadge JE and Fidler IJ: AACR centennial
series: the biology of cancer metastasis: historical perspective.
Cancer Res. 70:5649–5669. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Valastyan S and Weinberg RA: MicroRNAs:
Crucial multitasking components in the complex circuitry of tumor
metastasis. Cell Cycle. 8:3506–3512. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu K, Zhang C, Li T, Ding Y, Tu T, Zhou
F, Qi W, Chen H and Sun X: Let-7a inhibits growth and migration of
breast cancer cells by targeting HMGA1. Int J Oncol. 46:2526–2534.
2015.PubMed/NCBI
|
|
23
|
Fujita S, Ito T, Mizutani T, Minoguchi S,
Yamamichi N, Sakurai K and Iba H: miR-21 Gene expression triggered
by AP-1 is sustained through a double-negative feedback mechanism.
J Mol Biol. 378:492–504. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dillhoff M, Liu J, Frankel W, Croce C and
Bloomston M: MicroRNA-21 is overexpressed in pancreatic cancer and
a potential predictor of survival. J Gastrointest Surg.
12:2171–2176. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gao W, Yu Y, Cao H, Shen H, Li X, Pan S
and Shu Y: Deregulated expression of miR-21, miR-143 and miR-181a
in non small cell lung cancer is related to clinicopathologic
characteristics or patient prognosis. Biomed Pharmacother.
64:399–408. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Griffin CA, Hawkins AL, Packer RJ, Rorke
LB and Emanuel BS: Chromosome abnormalities in pediatric brain
tumors. Cancer Res. 48:175–180. 1988.PubMed/NCBI
|
|
27
|
Kasahara K, Taguchi T, Yamasaki I, Kamada
M, Yuri K and Shuin T: Detection of genetic alterations in advanced
prostate cancer by comparative genomic hybridization. Cancer Genet
Cytogenet. 137:59–63. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu GJ, Sinclair CS, Paape J, Ingle JN,
Roche PC, James CD and Couch FJ: 17q23 amplifications in breast
cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes. Cancer
Res. 60:5371–5375. 2000.PubMed/NCBI
|
|
29
|
Teng Y, Manavalan TT, Hu C, Medjakovic S,
Jungbauer A and Klinge CM: Endocrine disruptors fludioxonil and
fenhexamid stimulate miR-21 expression in breast cancer cells.
Toxicol Sci. 131:71–83. 2013. View Article : Google Scholar :
|
|
30
|
Yanaihara N, Caplen N, Bowman E, Seike M,
Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et
al: Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang M, Shen H, Qiu C, Ni Y, Wang L, Dong
W, Liao Y and Du J: High expression of miR-21 and miR-155 predicts
recurrence and unfavourable survival in non-small cell lung cancer.
Eur J Cancer. 49:604–615. 2013. View Article : Google Scholar
|
|
32
|
Markou A, Tsaroucha EG, Kaklamanis L,
Fotinou M, Georgoulias V and Lianidou ES: Prognostic value of
mature microRNA-21 and microRNA-205 overexpression in non-small
cell lung cancer by quantitative real-time RT-PCR. Clin Chem.
54:1696–1704. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cho WC, Chow AS and Au JS: Restoration of
tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung
adenocarcinoma patients with epidermal growth factor receptor
mutation. Eur J Cancer. 45:2197–2206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Seike M, Goto A, Okano T, Bowman ED,
Schetter AJ, Horikawa I, Mathe EA, Jen J, Yang P, Sugimura H, et
al: MiR-21 is an EGFR-regulated anti-apoptotic factor in lung
cancer in never-smokers. Proc Natl Acad Sci USA. 106:12085–12090.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Meng F, Henson R, Wehbe-Janek H, Ghoshal
K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the
PTEN tumor suppressor gene in human hepatocellular cancer.
Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bihrer V, Waidmann O, Friedrich-Rust M,
Forestier N, Susser S, Haupenthal J, Welker M, Shi Y,
Peveling-Oberhag J, Polta A, et al: Serum microRNA-21 as marker for
necroinflammation in hepatitis C patients with and without
hepatocellular carcinoma. PLoS One. 6:e269712011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kanaan Z, Rai SN, Eichenberger MR, Roberts
H, Keskey B, Pan J and Galandiuk S: Plasma miR-21: A potential
diagnostic marker of colorectal cancer. Ann Surg. 256:544–551.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu CW, Ng SS, Dong YJ, Ng SC, Leung WW,
Lee CW, Wong YN, Chan FK, Yu J and Sung JJ: Detection of miR-92a
and miR-21 in stool samples as potential screening biomarkers for
colorectal cancer and polyps. Gut. 61:739–745. 2012. View Article : Google Scholar
|
|
39
|
Li T, Li RS, Li YH, Zhong S, Chen YY,
Zhang CM, Hu MM and Shen ZJ: miR-21 as an independent biochemical
recurrence predictor and potential therapeutic target for prostate
cancer. J Urol. 187:1466–1472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang CH, Yue J, Fan M and Pfeffer LM: IFN
induces miR-21 through a signal transducer and activator of
transcription 3-dependent pathway as a suppressive negative
feedback on IFN-induced apoptosis. Cancer Res. 70:8108–8116. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Catto JW, Miah S, Owen HC, Bryant H, Myers
K, Dudziec E, Larré S, Milo M, Rehman I, Rosario DJ, et al:
Distinct microRNA alterations characterize high- and low-grade
bladder cancer. Cancer Res. 69:8472–8481. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Moriyama T, Ohuchida K, Mizumoto K, Yu J,
Sato N, Nabae T, Takahata S, Toma H, Nagai E and Tanaka M:
MicroRNA-21 modulates biological functions of pancreatic cancer
cells including their proliferation, invasion, and chemoresistance.
Mol Cancer Ther. 8:1067–1074. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu M, Wu H, Liu T, Li Y, Wang F, Wan H,
Li X and Tang H: Regulation of the cell cycle gene, BTG2, by miR-21
in human laryngeal carcinoma. Cell Res. 19:828–837. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hiyoshi Y, Kamohara H, Karashima R, Sato
N, Imamura Y, Nagai Y, Yoshida N, Toyama E, Hayashi N, Watanabe M,
et al: MicroRNA-21 regulates the proliferation and invasion in
esophageal squamous cell carcinoma. Clin Cancer Res. 15:1915–1922.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Alder H, Taccioli C, Chen H, Jiang Y,
Smalley KJ, Fadda P, Ozer HG, Huebner K, Farber JL, Croce CM, et
al: Dysregulation of miR-31 and miR-21 induced by zinc deficiency
promotes esophageal cancer. Carcinogenesis. 33:1736–1744. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yamanaka Y, Tagawa H, Takahashi N,
Watanabe A, Guo YM, Iwamoto K, Yamashita J, Saitoh H, Kameoka Y,
Shimizu N, et al: Aberrant overexpression of microRNAs activate AKT
signaling via down-regulation of tumor suppressors in natural
killer-cell lymphoma/leukemia. Blood. 114:3265–3275. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li J, Huang H, Sun L, Yang M, Pan C, Chen
W, Wu D, Lin Z, Zeng C, Yao Y, et al: MiR-21 indicates poor
prognosis in tongue squamous cell carcinomas as an apoptosis
inhibitor. Clin Cancer Res. 15:3998–4008. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zaman MS, Shahryari V, Deng G, Thamminana
S, Saini S, Majid S, Chang I, Hirata H, Ueno K, Yamamura S, et al:
Up-regulation of microRNA-21 correlates with lower kidney cancer
survival. PLoS One. 7:e310602012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Gao W, Shen H, Liu L, Xu J, Xu J and Shu
Y: MiR-21 over-expression in human primary squamous cell lung
carcinoma is associated with poor patient prognosis. J Cancer Res
Clin Oncol. 137:557–566. 2011. View Article : Google Scholar
|
|
50
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Horvath CM: STAT proteins and
transcriptional responses to extracellular signals. Trends Biochem
Sci. 25:496–502. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Shuai K: Modulation of STAT signaling by
STAT-interacting proteins. Oncogene. 19:2638–2644. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Leaman DW, Leung S, Li X and Stark GR:
Regulation of STAT-dependent pathways by growth factors and
cytokines. FASEB J. 10:1578–1588. 1996.PubMed/NCBI
|
|
54
|
Schindler C and Brutsaert S: Interferons
as a paradigm for cytokine signal transduction. Cell Mol Life Sci.
55:1509–1522. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bromberg JF: Activation of STAT proteins
and growth control. BioEssays. 23:161–169. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Bowman T, Garcia R, Turkson J and Jove R:
STATs in oncogenesis. Oncogene. 19:2474–2488. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Bromberg JF, Wrzeszczynska MH, Devgan G,
Zhao Y, Pestell RG, Albanese C and Darnell JE Jr: Stat3 as an
oncogene. Cell. 98:295–303. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Catlett-Falcone R, Landowski TH, Oshiro
MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L,
Fernández-Luna JL, Nuñez G, et al: Constitutive activation of Stat3
signaling confers resistance to apoptosis in human U266 myeloma
cells. Immunity. 10:105–115. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Niu G, Wright KL, Huang M, Song L, Haura
E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, et al:
Constitutive Stat3 activity up-regulates VEGF expression and tumor
angiogenesis. Oncogene. 21:2000–2008. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Leong PL, Andrews GA, Johnson DE, Dyer KF,
Xi S, Mai JC, Robbins PD, Gadiparthi S, Burke NA, Watkins SF, et
al: Targeted inhibition of Stat3 with a decoy oligonucleotide
abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA.
100:4138–4143. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wen YH, Shi X, Chiriboga L, Matsahashi S,
Yee H and Afonja O: Alterations in the expression of PDCD4 in
ductal carcinoma of the breast. Oncol Rep. 18:1387–1393.
2007.PubMed/NCBI
|
|
62
|
Davis BN, Hilyard AC, Lagna G and Hata A:
SMAD proteins control DROSHA-mediated microRNA maturation. Nature.
454:56–61. 2008. View Article : Google Scholar : PubMed/NCBI
|
